As a reminder I have zero experience in oncology To my understanding HER-Vaxx was never designed or intended to be a standalone treatment, rather meant to be coupled with SoC to improve efficacy with minimal toxicity. The results from HORIZON showed improved OS for those treated with HER-Vaxx combination therapy vs. SoC only. An 80% CI is just fine in clinical trials, especially Phase 2. It's simply a lever to pull to help expedite trial recruitment as a smaller sample size is needed vs. a study powered at 95%. If IMU has confidence that their drug shows promise and is willing to play it a bit riskier in the clinic by utilizing a smaller sample size and CI, then so be it. That is their gamble to take.
Side note, it would be nice to have links to all the studies/data you're posting.
- Forums
- ASX - By Stock
- Why IMU is a multi multi bagger
As a reminder I have zero experience in oncology To my...
-
- There are more pages in this discussion • 774 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M |
Open | High | Low | Value | Volume |
5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
31 | 1854997 | 5.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.3¢ | 382882 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
27 | 1694499 | 0.052 |
37 | 4870470 | 0.051 |
51 | 4160179 | 0.050 |
17 | 2263068 | 0.049 |
19 | 954663 | 0.048 |
Price($) | Vol. | No. |
---|---|---|
0.053 | 282882 | 3 |
0.054 | 2751851 | 4 |
0.055 | 1611272 | 15 |
0.056 | 2792035 | 11 |
0.057 | 700330 | 7 |
Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |